Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Much has been learned about GLP-1s over many years, but little is understood about why the degree of response to them varies ...

Trump is “in peak physical and mental condition,” White House Press Secretary Karoline Leavitt told The Atlantic in an ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

On Wall Street, Charter Communications rose 1.8% after it said it agreed to merge with Cox Communications in a deal that ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

By Patrick Wingrove and Maggie Fick (Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...